Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Sufentanil doses in pediatric adenotonsillectomy
NCT04067648Completed
- Sponsor
- Tongji Hospital
- Start
- Jul 2020
- Primary completion
- Dec 2022
- Modality
- Orthosteric Ligands
- Countries
- 1
01
Overview
Randomised, double-blind trial of sufentanil in adenoid hypertrophy and tonsillitis (3 arms), sponsored by Tongji Hospital. Primary endpoint: Adequate sufentanil dose at 24 hours. Started Jul 2020; status: completed.
02
Drugs
sufentanil
03
Conditions
adenoid hypertrophytonsillitis
Beyond the preview
Go deeper on NCT04067648.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04067648.